Baystate Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Baystate Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7	Closed	-$70	–	1074
2023 Q1	$70	Buy	+7	New	+$212	﹤0.01%	1020
2018 Q4	–	Sell	-2	Closed	-$1K	–	708
2018 Q3	$1K	Hold	2	–	–	﹤0.01%	618
2018 Q2	$1K	Buy	+2	New	+$2.31K	﹤0.01%	629

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Baystate Wealth Management's NKTR Position: Q2 2023 in Review

Baystate Wealth Management sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 7 shares — an estimated $70 sold.

Baystate Wealth Management first reported a position in NKTR in Q2 2018 and held it in 3 quarters. The position peaked at $1K in Q3 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Baystate Wealth Management reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Baystate Wealth Management sold 7 Nektar Therapeutics shares in Q2 2023, an estimated $70.
Baystate Wealth Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 3 quarters.
Baystate Wealth Management's Nektar Therapeutics position peaked at $1K in Q3 2018.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Baystate Wealth Management's 13F filing for Q2 2023, filed 2 Aug 2023.